title: [A meta-analysis on efficacy of antifibrinolytic agents during perioperative period in patients undergoing coronary artery bypass grafting treated with antiplatelet agents].
abstract: OBJECTIVE
  To evaluate the efficacy of antifibrinolytic agents in coronary artery bypass grafting (CABG) patients receiving antiplatelet.
  
  
  METHODS
  We searched PubMed, EMbase, Highwire, CENTREN and its affiliated clinical trial registration data center, CBMdisc and CNKI databases from 2000 to 2010. Randomized controlled trials investigating the efficacy of anti-fibrinolytic agents (aprotinin and tranexamic acid) in CABG patients were identified. Study selection and meta-analysis were conducted according to the Cochrane Handbook for systematic reviews. Date were extracted from these trials by 2 reviewers independently and analyzed by RevMan 5.0 software.
  
  
  RESULTS
  Eleven RCT trials (n = 725) were included and data confirmed the efficacy of antifibrinolytic therapy in terms of reducing bleeding within 24 hours after operation (MD = -306.5 ml, 95%CI: -351.52 to -261.52, P < 0.01), number of patients who need blood transfusion (OR = 0.37, 95%CI: 0.26 to 0.51, P < 0.01), amount of blood transfusion (MD = -0.59 U, 95%CI: -0.69 to -0.50, P < 0.01), surgical re-exploration(OR = 0.27, 95%CI: 0.09 to 0.78, P = 0.02), and thrombotic events (OR = 0.49, 95%CI: 0.25 to 0.97, P = 0.04) in CABG patients receiving antiplatelet, while compared with blank treatment.
  
  
  CONCLUSIONS
  This analysis showed that antifibrinolytic agents are effective for reducing bleeding within 24 hours after operation, amount of blood transfusion, surgical re-exploration and do not increase the incidence of thrombotic events in CABG patients receiving antiplatelet before operation.
authors.affiliation: First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China.
authors.forename: Hai-ping
authors.initials: HP
authors.lastname: Ma
authors.forename: Nuerbiyan
authors.initials: N
authors.lastname: Keyoumu
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
mesh_terms: D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D006801:Humans; D059035:Perioperative Period; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D010975:Platelet Aggregation Inhibitors